Automated structural imaging analysis detects premanifest Huntington's disease neurodegeneration within 1 year

Movement Disorders

Volumn 26, Issue 8, 2011, Pages 1481-1488

  Majid, D S Adnan ^a   Stoffers, Diederick ^b   Sheldon, Sarah ^c   Hamza, Samar ^c   Thompson, Wesley K ^d   Goldstein, Jody ^c   Corey Bloom, Jody ^c   Aron, Adam R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Longitudinal atrophy; MRI biomarker; Premanifest HD

Indexed keywords

ADULT; ARTICLE; AUTOMATION; BASAL GANGLION; BRAIN ATROPHY; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUNTINGTON CHOREA; IMAGE ANALYSIS; IMAGE QUALITY; LONGITUDINAL STUDY; MALE; NERVE DEGENERATION; NEUROIMAGING; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SAMPLE SIZE;

ADULT; BRAIN; CASE-CONTROL STUDIES; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; HUMANS; HUNTINGTON DISEASE; IMAGE PROCESSING, COMPUTER-ASSISTED; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVE DEGENERATION;

EID: 79960617269     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23656     Document Type: Article

References (42)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-983.
2. Beal MF, Ferrante RJ. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci 2004; 5: 373-384.
3. Bonelli RM, Wenning GK, Kapfhammer HP. Huntington's disease: present treatments and future therapeutic modalities. Int Clin Psychopharmacol 2004; 19: 51-62.
4. Handley OJ, Naji JJ, Dunnett SB, Rosser AE. Pharmaceutical, cellular and genetic therapies for Huntington's disease. Clin Sci 2006; 110: 73-88.
5. Fecke W, Gianfriddo M, Gaviraghi G, et al. Small molecule drug discovery for Huntington's Disease. Drug Discov Today 2009; 14: 453-464.
6. Gil JM, Rego AC. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease. Brain Res Rev 2009; 59: 410-431.
7. Mestre T, Ferreira J, Coelho MM, et al. Therapeutic interventions for disease progression in Huntington's disease. Cochrane Database Syst Rev 2009; 8: CD006455.
8. Bohanna I, Georgiou-Karistianis N, Hannan AJ, Egan GF. Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease. Brain Res Rev 2008; 58: 209-225.
9. Hersch SM, Rosas HD. Neuroprotection for Huntington's disease: ready, set, slow. Neurotherapeutics 2008; 5: 226-236.
10. Paulsen JS. Biomarkers to predict and track diseases. Lancet Neurol 2009; 8: 776-777.
11. Aylward EH. Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease. Brain Res Bull 2007; 72: 152-158.
12. Aylward E, Li Q, Stine O, et al. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 1997; 48: 394-399.
13. Aylward EH, Sparks BF, Field KM, et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004; 63: 66-72.
14. Hobbs NZ, Henley SMD, Wild EJ, et al. Automated quantification of caudate atrophy by local registration of serial MRI: evaluation and application in Huntington's disease. Neuroimage 2009; 47: 1659-1665.
15. Kipps CM, Duggins AJ, Mahant N, et al. Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study. J Neurol Neurosurg Psychiatr 2005; 76: 650-655.
16. Rosas HD, Hevelone ND, Zaleta AK, et al. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 2005; 65: 745-747.
17. Thieben MJ, Duggins AJ, Good CD, et al. The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain 2002; 125: 1815-1828.
18. Stoffers D, Sheldon S, Kuperman JM, et al. Contrasting gray and white matter changes in preclinical Huntington disease: an MRI study. Neurology 2010; 74: 1208-1216.
19. Ciarmiello A, Cannella M, Lastoria S, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med 2006; 47: 215-222.
20. Squitieri F, Cannella M, Simonelli M, et al. Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease. CNS Neurosci Ther 2009; 15: 1-11.
21. Weaver KE, Richards TL, Liang O, et al. Longitudinal diffusion tensor imaging in Huntington's disease. Exp Neurol 2009.
22. Smith S, De Stefano N, Jenkinson M, Matthews P. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 2001; 25: 466-475.
23. Smith S, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002; 17: 479-489.
24. Folstein M, Folstein S, McHugh P. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
25. The Huntington's Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996; 11: 136-142.
26. Aylward EH, Codori AM, Barta PE, et al. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol 1996; 53: 1293-1296.
27. Langbehn DR, Brinkman RR, Falush D, et al. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 2004; 65: 267-277.
28. Smith S, Jenkinson M, Woolrich M, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004; 23( Suppl 1): S208-S219.
29. Woolrich MW, Jbabdi S, Patenaude B, et al. Bayesian analysis of neuroimaging data in FSL. Neuroimage 2009; 45: S173-S186.
30. Smith S. Fast robust automated brain extraction. Hum Brain Mapp 2002; 17: 143-155.
31. Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 2002; 17: 825-841.
32. Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal 2001; 5: 143-156.
33. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging 2001; 20: 45-57.
34. Bartsch AJ, Bendszus N, De Stefano N, et al. Extending SIENA for a multi-subject statistical analysis of sample-specific cerebral edge shifts: substantiation of early brain regeneration through abstinence from alcoholism. Tenth International Conference on Functional Mapping of the Human Brain, 2004.
35. Hua X, Lee S, Hibar DP, et al. Mapping Alzheimer's disease progression in 1309 MRI scans: power estimates for different inter-scan intervals. Neuroimage 2010; 51: 63-75.
36. Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp 2002; 15: 1-25.
37. de Boo G, Tibben A, Hermans J, Maat A, Roos RA. Subtle involuntary movements are not reliable indicators of incipient Huntington's disease. Mov Disord 1998; 13: 96-99.
38. Sormani M, Rovaris M, Valsasina P, Wolinsky J, Comi G, Filippi M. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology 2004; 62: 1432-1434.
39. Paulsen JS, Nopoulos PC, Aylward E, et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull 2010.
40. Paulsen JS, Magnotta VA, Mikos AE, et al. Brain structure in preclinical Huntington's disease. Biol Psychiatry 2006; 59: 57-63.
41. Nopoulos P, Magnotta V, Mikos A, Paulson H, Andreasen N, Paulsen J. Morphology of the cerebral cortex in preclinical Huntington's disease. Am J Psychiatry 2007; 164: 1428-1434.
42. Langbehn DR, Hayden MR, Paulsen JS, Group P-HIotHS. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 397-408.